{"id":"NCT03478787","sponsor":"AbbVie","briefTitle":"Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis","officialTitle":"A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-05-08","primaryCompletion":"2020-07-08","completion":"2020-07-08","firstPosted":"2018-03-27","resultsPosted":"2021-07-13","lastUpdate":"2021-07-13"},"enrollment":327,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"risankizumab","otherNames":["ABBV-066","BI 655066","SKYRIZI"]},{"type":"DRUG","name":"secukinumab","otherNames":["Cosentyx"]}],"arms":[{"label":"Risankizumab","type":"EXPERIMENTAL"},{"label":"Secukinumab","type":"ACTIVE_COMPARATOR"}],"summary":"The main objective of this study is to evaluate the efficacy and safety of risankizumab compared with secukinumab for the treatment of adult subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy.","primaryOutcome":{"measure":"Percentage of Participants With a 90% Reduction From Baseline Psoriasis Area and Severity Index (PASI 90) at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Secukinumab","deltaMin":65.6,"sd":null},{"arm":"Risankizumab","deltaMin":73.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":null,"healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":61,"countries":["United States","Canada","France","Germany","Italy","Netherlands","Poland","Spain","United Kingdom"]},"refs":{"pmids":["35050485"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":163},"commonTop":["NASOPHARYNGITIS","UPPER RESPIRATORY TRACT INFECTION","HEADACHE","ARTHRALGIA","DIARRHOEA"]}}